Cures Within Reach (CWR) leverages the speed, safety and cost-effectiveness of medical repurposing: testing already approved therapies for unsolved diseases. CWR focuses on POC trials that, if successful, catalyze follow-on funding to build the clinical evidence required for regulatory approval or more often, for off-label use. CWR is institution-agnostic, geography-agnostic and disease-agnostic, allowing its neutral selection process to de-risk treatment options while building the pipeline for follow-on funders. For over 15 years, CWR’s funding of over $10 million to more than 140 repurposing trials has helped to catalyze over $103 million in follow-on funding. In 2023 alone, CWR-funded researchers raised over $16 million in follow-on funding for trials.
Cures Within Reach (CWR) leverages the speed, safety and cost-effectiveness of medical repurposing: testing already approved therapies for unsolved diseases. CWR focuses on POC trials that, if successful, catalyze follow-on funding to build the clinical evidence required for regulatory approval or more often, for off-label use. CWR is institution-agnostic, geography-agnostic and disease-agnostic, allowing its neutral selection process to de-risk treatment options while building the pipeline for follow-on funders. For over 15 years, CWR’s funding of over $10 million to more than 140 repurposing trials has helped to catalyze over $103 million in follow-on funding. In 2023 alone, CWR-funded researchers raised over $16 million in follow-on funding for trials.